---
title: "Executive Director Chen Wenyuan reduced his holdings in SUNEVISION by 300,000 shares at a price of approximately HKD 6.31 per share"
description: "According to the latest information from the Hong Kong Stock Exchange, on May 12, Executive Director Chen Wenyuan reduced his holdings in SUNEVISION by 300,000 shares, at a price of HKD 6.3123 per sha"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/240521300.md"
published_at: "2025-05-16T07:40:02.000Z"
---

# Executive Director Chen Wenyuan reduced his holdings in SUNEVISION by 300,000 shares at a price of approximately HKD 6.31 per share

> According to the latest information from the Hong Kong Stock Exchange, on May 12, Executive Director Chen Wenyuan reduced his holdings in SUNEVISION by 300,000 shares, at a price of HKD 6.3123 per share, totaling approximately HKD 1.8937 million. After the increase, the latest number of shares held is 3.412 million, with a latest holding ratio of 0.14%

According to the latest information from the Hong Kong Stock Exchange, on May 12th, Executive Director Chen Wenyuan reduced his holdings in SUNEVISION (01686) by 300,000 shares, at a price of HKD 6.3123 per share, totaling approximately HKD 1.8937 million. After the increase, the latest number of shares held is 3.412 million, with a latest holding ratio of 0.14%

### Related Stocks

- [01686.HK - SUNEVISION](https://longbridge.com/en/quote/01686.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Standard Chartered PLC (OTCMKTS:SCBFF) Sees Significant Growth in Short Interest | Standard Chartered PLC (OTCMKTS:SCBFF) experienced a significant increase in short interest, rising 21.1% to 210,583 sha | [Link](https://longbridge.com/en/news/276119010.md) |
| Will China Literature Turn The Page? | China Literature Ltd. expects a net loss of up to 850 million yuan for last year, primarily due to a 1.8 billion yuan go | [Link](https://longbridge.com/en/news/276113491.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/en/news/276035104.md) |
| UBS Remains a Buy on Netease Inc (9999) | UBS analyst maintained a Buy rating on Netease Inc yesterday and set a price target of HK$280.80.Valentine's Day Sale -  | [Link](https://longbridge.com/en/news/275830949.md) |
| Italy says it stands ready to train police in Gaza | Italy's Foreign Minister Antonio Tajani announced the country's readiness to train police forces in Gaza and the Palesti | [Link](https://longbridge.com/en/news/276056959.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.